Phaseline

Companies › Medicenna Therapeutics

Medicenna Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MDNA11
Beta-only IL-2 receptor agonist fused to albumin
IL2Phase 1Advanced Solid TumorOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05086692MDNA11Phase 1Advanced Solid TumorOncologyOct 2028

From the company's SEC filings

Cash and short-term investments of 66m CAD on 2023-03-31; operating cash outflow about 52m CAD a year; runway about 15 months at that burn, to Jul 2024

Targets

IL2 (1)

Companies with the same targets

Innovent Biologics (Suzhou) AstraZeneca Coya Therapeutics Synthekine Nektar Therapeutics HCW Biologics Asher Biotherapeutics Regeneron Pharmaceuticals Salspera Iovance Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.